Microbot Medical Inc. (NASDAQ:MBOT) was the recipient of a large increase in short interest in July. As of July 31st, there was short interest totalling 1,436,514 shares, an increase of 24.4% from the July 14th total of 1,154,654 shares. Approximately 41.5% of the shares of the stock are short sold. Based on an average trading volume of 1,409,625 shares, the short-interest ratio is presently 1.0 days.

Microbot Medical (NASDAQ:MBOT) opened at 1.11 on Friday. The company’s market capitalization is $41.06 million. Microbot Medical has a 12 month low of $1.03 and a 12 month high of $18.18. The stock’s 50 day moving average price is $1.25 and its 200 day moving average price is $3.74.

Microbot Medical (NASDAQ:MBOT) last posted its earnings results on Monday, August 14th. The biotechnology company reported ($0.04) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.48) by $0.44. Equities research analysts anticipate that Microbot Medical will post ($25.02) earnings per share for the current fiscal year.

In other Microbot Medical news, major shareholder Leon Lewkowicz sold 71,224 shares of the firm’s stock in a transaction dated Friday, June 16th. The stock was sold at an average price of $1.67, for a total value of $118,944.08. Following the sale, the insider now owns 3,078,214 shares of the company’s stock, valued at approximately $5,140,617.38. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Company insiders own 1.30% of the company’s stock.

A hedge fund recently raised its stake in Microbot Medical stock. Vanguard Group Inc. increased its position in Microbot Medical Inc. (NASDAQ:MBOT) by 252.2% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 159,992 shares of the biotechnology company’s stock after buying an additional 114,561 shares during the period. Vanguard Group Inc. owned approximately 0.43% of Microbot Medical worth $228,000 at the end of the most recent reporting period. 1.13% of the stock is owned by institutional investors.

Separately, ValuEngine raised Microbot Medical from a “strong sell” rating to a “sell” rating in a report on Friday, June 2nd.

COPYRIGHT VIOLATION NOTICE: This piece was published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this piece on another domain, it was illegally copied and reposted in violation of United States & international copyright law. The legal version of this piece can be accessed at https://www.thecerbatgem.com/2017/08/18/short-interest-in-microbot-medical-inc-mbot-expands-by-24-4.html.

About Microbot Medical

Microbot Medical Inc, formerly StemCells, Inc, is a medical device company. The Company specializes in the researching, designing, developing and commercializing transformational micro-robotic medical technologies leveraging the artificial and natural lumens within the human body. It is engaged in developing its two product candidates: the Self Cleaning Shunt (SCS) for the treatment of hydrocephalus and normal pressure hydrocephalus (NPH), and TipCAT, a self-propelling, semi-disposable endoscope that the Company is developing for use in colonoscopy procedures.

Receive News & Stock Ratings for Microbot Medical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Microbot Medical Inc. and related stocks with our FREE daily email newsletter.